Arena Pharmaceuticals - ARNA Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ARNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARNA, but not buy additional shares or sell existing shares.
View ARNA analyst ratings or view top-rated stocks.

1 brokerages have issued 12-month target prices for Arena Pharmaceuticals' shares. Their ARNA share price forecasts range from $100.00 to $100.00. On average, they anticipate the company's stock price to reach $100.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price.
View analysts price targets for ARNA or view top-rated stocks among Wall Street analysts.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.53) by $0.68. During the same period in the previous year, the company posted ($1.69) EPS.

Arena Pharmaceuticals's stock reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

16 employees have rated Arena Pharmaceuticals Chief Executive Officer Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

One share of ARNA stock can currently be purchased for approximately $99.99.

Arena Pharmaceuticals (NASDAQ:ARNA) has a market capitalization of $6.17 billion and generates $50,000.00 in revenue each year. The biopharmaceutical company earns $-616,430,000.00 in net income (profit) each year or ($10.13) on an earnings per share basis.

The company employs 448 workers across the globe.

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.arenapharm.com. The biopharmaceutical company can be reached via phone at (858) 453-7200, via email at ir@arenapharm.com, or via fax at 858-453-7210.